Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.58 |
| ▸ | BCHE | P06276 | 6/20 | 0.57 |
| ▸ | BACE1 | P56817 | 6/20 | 0.57 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4041606 | 1.00 | ACHE (0.58) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL17986116 | 1.00 | ACHE (0.58) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL22829165 | 0.89 | CYP2D6 (0.66) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL5304176 | 0.89 | CYP2D6 (0.66) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL1232375 | 0.89 | ACHE (0.67) | ACHEBCHEBACE1CCR3ALDH1A1 | |
| SCHEMBL5851129 | 0.88 | CYP2D6 (0.59) | ACHEBCHEBACE1CCR3CYP1A2 | |
| Hydrochloric Acid SCHEMBL28439633 | 0.87 | ACHE (0.65) | ACHEBCHEBACE1CCR3ALDH1A1 | |
| SCHEMBL3846308 | 0.80 | ALDH1A1 (0.58) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL6972698 | 0.79 | ACHE (0.59) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL5858096 | 0.79 | ACHE (0.59) | ACHEBCHEBACE1CCR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256464-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2022-05-11 | — | — | EP | claimed |
| US-10004728-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-06-26 | — | — | US | claimed |
| US-20170119753-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-04 | — | — | US | claimed |
| US-9579314-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-02-28 | — | — | US | claimed |
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-18 | — | — | US | claimed |
| EP-3256464-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2022-05-11 | — | — | EP | disclosed |
| US-20030100588-A1 | Indole-type inhibitors of p38 kinase | SCIOS, INC. | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | ACHE 309/4885BCHE 718/4885BACE1 898/4885 |
| US-20030100588-A1 | Indole-type inhibitors of p38 kinase | CNKSR1, MAPK1, MAP2K6 | ACHE 4718/4885BCHE 4795/4885BACE1 3717/4885 |
| US-10004728-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | ACHE 309/4885BCHE 718/4885BACE1 898/4885 |
| US-20170119753-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | ACHE 309/4885BCHE 718/4885BACE1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.